Log in

Relevant bibliographies by topics / PASH syndrome / Journal articles

To see the other types of publications on this topic, follow the link: PASH syndrome.

Journal articles on the topic 'PASH syndrome'

Author: Grafiati

Published: 1 April 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'PASH syndrome.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Sai Lahari, R., R. Uday Kiran, M. Hemalatha, and A. Vijaya Mohan Rao. "PASH SYNDROME CO-EXISTING WITH RHEUMATIC HEART DISEASE AND SEVERE MITRAL VALVE REGURGITATION: A RARE CASE REPORT." International Journal of Advanced Research 11, no. 01 (January 31, 2023): 239–41. http://dx.doi.org/10.21474/ijar01/16012.

Full text

Abstract:

Pyoderma gangrenosum, Acne, and Hidradenitis Suppurativa (PASH) is a rare inflammatory syndrome, the exact etiology and pathogenesis of which remains unknown. PASH syndrome belongs to the spectrum of Interleukin-1 driven auto-inflammatory diseases.InPatientsdiagnosed with PASH syndrome, various ways of treatment are available with individual differences in efficacy. We reporta new case of PASH syndrome that highlights the features of this rare condition and is coexisting with rheumatic heart disease and severe mitral valve regurgitation.

APA, Harvard, Vancouver, ISO, and other styles

2

Chaoui, Rhizlane, Zakia Douhi, and Selma El Kadiri. "A case of PASH syndrome." Our Dermatology Online 11, e (July 19, 2020): e60.1-e60.2. http://dx.doi.org/10.7241/ourd.2020e.60.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Gracia-Cazaña, Tamara, María Frias, Rosa Roselló, Jesús Vera-Álvarez, and Yolanda Gilaberte. "PASH syndrome associated with osteopoikilosis." International Journal of Dermatology 54, no. 9 (July 14, 2015): e369-e371. http://dx.doi.org/10.1111/ijd.12827.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

McCarthy, S., C. C. Foley, V. Dvorakova, C. Quinlan, M. Murphy, and M. Maher. "PASH syndrome with bony destruction." Clinical and Experimental Dermatology 44, no. 8 (January 21, 2019): 918–20. http://dx.doi.org/10.1111/ced.13909.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Cawen, Irina, Jorge Navarrete, and Caroline Agorio. "PASH syndrome: a novel surgical approach." Anais Brasileiros de Dermatologia 97, no. 1 (January 2022): 121–23. http://dx.doi.org/10.1016/j.abd.2020.08.034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Zhang, Xiaofeng, Yanyan He, Haoxiang Xu, and Baoxi Wang. "First PSENEN mutation in PASH syndrome." Journal of Dermatology 47, no. 11 (August 7, 2020): 1335–37. http://dx.doi.org/10.1111/1346-8138.15527.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Brochet, T., C. Joachim-Naepels, A. Dadban, L. A. Séméria, J. P. Arnault, F. Lombart, G. Chaby, and C. Lok. "Un cas de syndrome PASH traité par sécukinumab." Annales de Dermatologie et de Vénéréologie - FMC 2, no. 8 (November 2022): A243. http://dx.doi.org/10.1016/j.fander.2022.10.059.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Gönül, Müzeyyen, Bengu Cevirgen Cemil, Havva Ozge Keseroglu, and Havva Kaya Akis. "New Described Dermatological Disorders." BioMed Research International 2014 (2014): 1–13. http://dx.doi.org/10.1155/2014/616973.

Full text

Abstract:

Many advances in dermatology have been made in recent years. In the present review article, newly described disorders from the last six years are presented in detail. We divided these reports into different sections, including syndromes, autoinflammatory diseases, tumors, and unclassified disease. Syndromes included are “circumferential skin creases Kunze type” and “unusual type of pachyonychia congenita or a new syndrome”; autoinflammatory diseases include “chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome,” “pyoderma gangrenosum, acne, and hidradenitis suppurativa (PASH) syndrome,” and “pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH) syndrome”; tumors include “acquired reactive digital fibroma,” “onychocytic matricoma and onychocytic carcinoma,” “infundibulocystic nail bed squamous cell carcinoma,” and “acral histiocytic nodules”; unclassified disorders include “saurian papulosis,” “symmetrical acrokeratoderma,” “confetti-like macular atrophy,” and “skin spicules,” “erythema papulosa semicircularis recidivans.”

APA, Harvard, Vancouver, ISO, and other styles

9

Gul, Muhammad, Vivek Singam, Cody Hanson, Brett Neill, Daniel Aires, and Anand Rajpara. "Remission of Refractory PASH Syndrome Using Ixekizumab and Doxycycline." Journal of Drugs in Dermatology 19, no. 11 (October 1, 2020): 1124–25. http://dx.doi.org/10.36849/jdd.2020.1123.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Baroud, Sumer, Jim Wu, and Christos C. Zouboulis. "Acne Syndromes and Mosaicism." Biomedicines 9, no. 11 (November 21, 2021): 1735. http://dx.doi.org/10.3390/biomedicines9111735.

Full text

Abstract:

Abnormal mosaicism is the coexistence of cells with at least two genotypes, by the time of birth, in an individual derived from a single zygote, which leads to a disease phenotype. Somatic mosaicism can be further categorized into segmental mosaicism and nonsegmental somatic mosaicism. Acne is a chronic illness characterized by inflammatory changes around and in the pilosebaceous units, commonly due to hormone- and inflammatory signaling-mediated factors. Several systemic disorders, such as congenital adrenal hyperplasia, polycystic ovarian syndrome, and seborrhoea-acne-hirsutism-androgenetic alopecia syndrome have classically been associated with acne. Autoinflammatory syndromes, including PAPA, PASH, PAPASH, PsAPASH, PsaPSASH, PASS, and SAPHO syndromes include acneiform lesions as a key manifestation. Mosaic germline mutations in the FGFR2 gene have been associated with Apert syndrome and nevus comedonicus, two illnesses that are accompanied by acneiform lesions. In this review, we summarize the concept of cutaneous mosaicism and elaborate on acne syndromes, as well as acneiform mosaicism.

APA, Harvard, Vancouver, ISO, and other styles

11

Lamiaux, M. C., F. Dabouz, M. Wantz, D. Lebas, D. Courivaud, and P. Modiano. "PASH syndrome : efficacité rifampicine-clindamycine sur un pyoderma gangrenosum résistant." Annales de Dermatologie et de Vénéréologie 143, no. 12 (December 2016): S250. http://dx.doi.org/10.1016/j.annder.2016.09.345.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Devergne, C., P. Schoenlaub, and A. Saraux. "Efficacité des inhibiteurs de l’interleukine 17 dans le syndrome PASH." Annales de Dermatologie et de Vénéréologie 146, no. 12 (December 2019): A212. http://dx.doi.org/10.1016/j.annder.2019.09.317.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Staub, J., N. Pfannschmidt, R. Strohal, M. Braun-Falco, P. Lohse, S. Goerdt, and M. Leverkus. "Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone." Journal of the European Academy of Dermatology and Venereology 29, no. 11 (October 28, 2014): 2243–47. http://dx.doi.org/10.1111/jdv.12765.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Wargo, Jeffrey J., and Brian T. Emmer. "Systemic Inflammation Gone Awry: PASH Syndrome and Temporomandibular Joint Ankylosis." American Journal of Medicine 129, no. 4 (April 2016): e1-e3. http://dx.doi.org/10.1016/j.amjmed.2015.12.019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Niv, Dorene, James A. Ramirez, and David P. Fivenson. "Pyoderma gangrenosum, acne, and hidradenitis suppurativa (PASH) syndrome with recurrent vasculitis." JAAD Case Reports 3, no. 1 (January 2017): 70–73. http://dx.doi.org/10.1016/j.jdcr.2016.11.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Braun-Falco, Markus, Oleksandr Kovnerystyy, Peter Lohse, and Thomas Ruzicka. "Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)?a new autoinflammatory syndrome distinct from PAPA syndrome." Journal of the American Academy of Dermatology 66, no. 3 (March 2012): 409–15. http://dx.doi.org/10.1016/j.jaad.2010.12.025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Nedelcu, Roxana Ioana. "PASH Syndrome: Comparing Pathogenic Mechanism of Pyoderma Gangrenosum, Acne and Suppurative Hidradenitis." American Journal of Biomedical Science & Research 11, no. 1 (November 30, 2020): 64–70. http://dx.doi.org/10.34297/ajbsr.2020.11.001587.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Duchatelet, S., S. Miskinyte, O. Join‐Lambert, M. ‐N Ungeheuer, C. Francès, A. Nassif, and A. Hovnanian. "First nicastrin mutation in PASH (pyoderma gangrenosum, acne and suppurative hidradenitis) syndrome." British Journal of Dermatology 173, no. 2 (June 11, 2015): 610–12. http://dx.doi.org/10.1111/bjd.13668.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Faffa, M. S., C. Paul, I. Touitou, and L. Misery. "Une nouvelle entité : le PASH syndrome (pyoderma gangrenosum, acné et hidradénite suppurée)." Annales de Dermatologie et de Vénéréologie 141, no. 12 (December 2014): S430—S431. http://dx.doi.org/10.1016/j.annder.2014.09.455.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

LI, CHENGRANG, HAOXIANG XU, and BAOXI WANG. "Is SAPHO Syndrome Linked to PASH Syndrome and Hidradenitis Suppurativa by Nicastrin Mutation? A Case Report." Journal of Rheumatology 45, no. 11 (August 1, 2018): 1605.3–1607. http://dx.doi.org/10.3899/jrheum.171007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Ursani, Mohammad A., Joan Appleyard, and Onome Whiteru. "Pyogenic Arthritis, Pyoderma Gangrenosum, Acne, Suppurative Hidradenitis (PA-PASH) Syndrome: An Atypical Presentation of a Rare Syndrome." American Journal of Case Reports 17 (August 17, 2016): 587–91. http://dx.doi.org/10.12659/ajcr.898027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Zagaria, Orlando, Angelo Ruggiero, Gabriella Fabbrocini, Lucia Gallo, Marco Romanelli, and Claudio Marasca. "Wound care, adalimumab, and multidisciplinary approach in a patient affected by PASH syndrome." International Wound Journal 17, no. 5 (May 22, 2020): 1528–31. http://dx.doi.org/10.1111/iwj.13403.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Calderón‐Castrat, X., D. Bancalari‐Díaz, C. Román‐Curto, A. Romo‐Melgar, D. Amorós‐Cerdán, L. A. Alcaraz‐Mas, E. Fernández‐López, and J. Cañueto. "PSTPIP 1 gene mutation in a pyoderma gangrenosum, acne and suppurative hidradenitis ( PASH ) syndrome." British Journal of Dermatology 175, no. 1 (April 19, 2016): 194–98. http://dx.doi.org/10.1111/bjd.14383.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Zivanovic, Dubravka, Iva Masirevic, Thomas Ruzicka, Markus Braun-Falco, and Milos Nikolic. "Pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) and polycystic ovary syndrome: Coincidentally or aetiologically connected?" Australasian Journal of Dermatology 58, no. 2 (February 2, 2016): e54-e59. http://dx.doi.org/10.1111/ajd.12438.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Chasset, F., C. Demongeot, R. Jonathan, M. Bagot, C. Baudry, H. Bachelez, and A. Petit. "Acné nodulaire, pyoderma gangrenosum et hidrosadénite suppurée (syndrome PASH) satellites d’une maladie de Crohn." Annales de Dermatologie et de Vénéréologie 140, no. 12 (December 2013): S558. http://dx.doi.org/10.1016/j.annder.2013.09.442.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Parisi, Paola, Federica Vinci, Filippo Di Meglio, Giovanni Marruzzo, Alessandro De Luca, Andrea Ascione, Luigi Vittori, and Diego Ribuffo. "Recurrent Extreme Bilateral Gigantomastia Caused by Pseudoangiomatous Stromal Hyperplasia (PASH) Syndrome: A Case Report." Plastic and Reconstructive Surgery - Global Open 11, no. 1 (January 2023): e4571. http://dx.doi.org/10.1097/gox.0000000000004571.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Nikolakis, Georgios, Katja Kreibich, Aristeidis Vaiopoulos, Katarzyna Kaleta, Joud Talas, Markus Becker, and Christos C. Zouboulis. "Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab." F1000Research 10 (May 13, 2021): 381. http://dx.doi.org/10.12688/f1000research.52100.1.

Full text

Abstract:

Syndromic hidradenitis suppurativa (HS) is a form of symptom constellations, which differs from the familial and genetic form and comprises predominantly osteoarticular manifestations. Many forms include pyoderma gangrenosum and acne (PASH), pyogenic arthritis (PAPASH), spondyloarthritis (PASS) and psoriatic arthritis (PsaPASH) and are categorized in the autoinflammatory syndromes. anti-TNF-α and anti-IL-1a blockade are between the therapeutic approaches that improve skin symptoms and prevent permanent osteoarticular damage. This case report refers to the successful treatment of a mixed phenotype of the aforementioned symptoms using the IL-17A inhibitor secukinumab after initial treatment with adalimumab. The therapy improved both cutaneous and reported osteoarticular symptoms. Different approaches for these recalcitrant HS syndromes are essential in order to achieve long-term remission for those patients.

APA, Harvard, Vancouver, ISO, and other styles

28

Nikolakis, Georgios, Katja Kreibich, Aristeidis Vaiopoulos, Katarzyna Kaleta, Joud Talas, Markus Becker, and Christos C. Zouboulis. "Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab." F1000Research 10 (July 16, 2021): 381. http://dx.doi.org/10.12688/f1000research.52100.2.

Full text

Abstract:

Syndromic hidradenitis suppurativa (HS) is a form of symptom constellations, which differs from the familial and genetic form and comprises predominantly osteoarticular manifestations. Many forms include pyoderma gangrenosum and acne (PASH), pyogenic arthritis (PAPASH), spondyloarthritis (PASS) and psoriatic arthritis (PsAPASH) and are categorized in the autoinflammatory syndromes. Anti-TNF-α and anti-IL-1a blockade are between the therapeutic approaches that improve skin symptoms and prevent permanent osteoarticular damage. This case report refers to the successful treatment of a mixed phenotype of the aforementioned symptoms using the IL-17A inhibitor secukinumab after initial treatment with adalimumab. The therapy improved both cutaneous and reported osteoarticular symptoms. Different approaches for these recalcitrant HS syndromes are essential in order to achieve long-term remission for those patients.

APA, Harvard, Vancouver, ISO, and other styles

29

Lamiaux, Marie, Fadia Dabouz, Maud Wantz, Damien Lebas, Audrey Lasek, Domitille Courivaud, and Philippe Modiano. "Successful combined antibiotic therapy with oral clindamycin and oral rifampicin for pyoderma gangrenosum in patient with PASH syndrome." JAAD Case Reports 4, no. 1 (January 2018): 17–21. http://dx.doi.org/10.1016/j.jdcr.2017.05.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Uitto, J., M. Faraji Zonooz, F. Sabbagh-Kermani, Z. Fattahi, M. Fadaee, M. Reza Akbari, R. Amiri, H. Vahidnezhad, H. Najmabadi, and A. Kariminejad. "159 PASH syndrome is not a genetically distinct entity but belongs to the spectrum of autoinflammatory skin phenotypes." Journal of Investigative Dermatology 136, no. 9 (September 2016): S188. http://dx.doi.org/10.1016/j.jid.2016.06.177.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Join-Lambert, Olivier, Sabine Duchatelet, Maïa Delage, Snaigune Miskinyte, Hélène Coignard, Nicolas Lemarchand, Murielle Alemy-Carreau, et al. "Remission of refractory pyoderma gangrenosum, severe acne, and hidradenitis suppurativa (PASH) syndrome using targeted antibiotic therapy in 4 patients." Journal of the American Academy of Dermatology 73, no. 5 (November 2015): S66—S69. http://dx.doi.org/10.1016/j.jaad.2015.07.040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Murphy, Bryan, Graham Morrison, and Pat Podmore. "Successful use of adalimumab to treat pyoderma gangrenosum, acne and suppurative hidradenitis (PASH syndrome) following colectomy in ulcerative colitis." International Journal of Colorectal Disease 30, no. 8 (January 7, 2015): 1139–40. http://dx.doi.org/10.1007/s00384-014-2110-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Hayden, Melvin R. "Hypothesis: Neuroglia Activation Due to Increased Peripheral and CNS Proinflammatory Cytokines/Chemokines with Neuroinflammation May Result in Long COVID." Neuroglia 2, no. 1 (August 30, 2021): 7–35. http://dx.doi.org/10.3390/neuroglia2010004.

Full text

Abstract:

The COVID-19 pandemic has paralleled the great Spanish flu pandemic of 1918–1919 in the United States. Previous historical accounts have strongly suggested a post-viral syndrome and, currently, a post-COVID-19 viral syndrome is unquestionable, which shares many of the characteristics of myalgic encephalomyelitis/chronic fatigue syndrome that is present globally. The original term for this post-acute sequela of SARS-CoV-2 (PASC) was termed long haulers by those who were affected with this syndrome and it is now termed long COVID (LC) or PASC. International researchers and clinicians are desperately trying to better understand the pathobiological mechanisms possibly involved in this syndrome. This review aims to summarize many of the cumulated findings associated with LC/PASC and provides supportive and representative illustrations and transmission electron micrographic remodeling changes within brain tissues associated with a stress type of injury as occurs in the classic db/db and novel BTBR ob/ob obesity and diabetes mellitus mice models. These models are utilized to merely provide a response to metabolic stress injury wound healing mechanisms that are also present in humans. This review posits that neuroglial activation and chronic neuroinflammation may be a common denominator for the development of the complex LC/PASC syndrome following acute COVID-19 due to SARS-CoV-2.

APA, Harvard, Vancouver, ISO, and other styles

34

Chung, Tae Hwan, and Antoine Azar. "Autonomic Nerve Involvement in Post-Acute Sequelae of SARS-CoV-2 Syndrome (PASC)." Journal of Clinical Medicine 12, no. 1 (December 22, 2022): 73. http://dx.doi.org/10.3390/jcm12010073.

Full text

Abstract:

The novel SARS-CoV-2 virus and resulting COVID-19 global pandemic emerged in 2019 and continues into 2022. While mortality from COVID-19 is slowly declining, a subset of patients have developed chronic, debilitating symptoms following complete recovery from acute infection with COVID-19. Termed as post-acute sequelae of SARS-CoV-2 syndrome (PASC), the underlying pathophysiology of PASC is still not well understood. Given the similarity between the clinical phenotypes of PASC and postural orthostatic tachycardia syndrome (POTS), it has been postulated that dysautonomia may play a role in the pathophysiology of PASC. However, there have been only a few studies that have examined autonomic function in PASC. In this retrospective study, we performed an analysis of autonomic nerve function testing in PASC patients and compared the results with those of POTS patients and healthy controls. Our results suggest that a significant number of PASC patients have abnormal autonomic function tests, and their clinical features are indistinguishable from POTS.

APA, Harvard, Vancouver, ISO, and other styles

35

Bisaccia, Giandomenico, Fabrizio Ricci, Vittoria Recce, Antonio Serio, Giovanni Iannetti, Anwar A. Chahal, Marcus Ståhlberg, Mohammed Yunus Khanji, Artur Fedorowski, and Sabina Gallina. "Post-Acute Sequelae of COVID-19 and Cardiovascular Autonomic Dysfunction: What Do We Know?" Journal of Cardiovascular Development and Disease 8, no. 11 (November 15, 2021): 156. http://dx.doi.org/10.3390/jcdd8110156.

Full text

Abstract:

Post-acute sequelae of SARS-CoV-2 (PASC), or long COVID syndrome, is emerging as a major health issue in patients with previous SARS-CoV-2 infection. Symptoms commonly experienced by patients include fatigue, palpitations, chest pain, dyspnea, reduced exercise tolerance, and “brain fog”. Additionally, symptoms of orthostatic intolerance and syncope suggest the involvement of the autonomic nervous system. Signs of cardiovascular autonomic dysfunction appear to be common in PASC and are similar to those observed in postural orthostatic tachycardia syndrome and inappropriate sinus tachycardia. In this review, we report on the epidemiology of PASC, discuss current evidence and possible mechanisms underpinning the dysregulation of the autonomic nervous system, and suggest nonpharmacological and pharmacological interventions to treat and relieve symptoms of PASC-associated dysautonomia.

APA, Harvard, Vancouver, ISO, and other styles

36

Cugno, Massimo, Alessandro Borghi, and Angelo V. Marzano. "PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and Treatment." American Journal of Clinical Dermatology 18, no. 4 (February 25, 2017): 555–62. http://dx.doi.org/10.1007/s40257-017-0265-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Cavigli, Luna, Chiara Fusi, Marta Focardi, Giulia Elena Mandoli, Maria Concetta Pastore, Matteo Cameli, Serafina Valente, et al. "Post-Acute Sequelae of COVID-19: The Potential Role of Exercise Therapy in Treating Patients and Athletes Returning to Play." Journal of Clinical Medicine 12, no. 1 (December 30, 2022): 288. http://dx.doi.org/10.3390/jcm12010288.

Full text

Abstract:

Post-acute sequelae of coronavirus disease 19 (COVID-19) (PASC) describe a wide range of symptoms and signs involving multiple organ systems occurring after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, representing a growing health problem also in the world of sport and the athletic population. Patients with PASC have new, returning, or persisting symptoms four or more weeks after the infection. Among the most frequent symptoms, patients complain of fatigue, dyspnea, exercise intolerance, and reduced functional capacity that interfere with everyday life activity. The role of exercise programs in PASC patients will be identified, and upcoming studies will establish the magnitude of their benefits. However, the benefits of exercise to counteract these symptoms are well known, and an improvement in cardiopulmonary fitness, functional status, deconditioning, and quality of life can be obtained in these patients, as demonstrated in similar settings. Based on this background, this review aims to summarise the current evidence about the PASC syndrome and the benefit of exercise in these patients and to provide a practical guide for the exercise prescription in PASC patients to help them to resume their functional status, exercise tolerance, prior activity levels, and quality of life, also considering the athletic population and their return to play and sports competitions.

APA, Harvard, Vancouver, ISO, and other styles

38

Paul, Bindu D., Marian D. Lemle, Anthony L. Komaroff, and Solomon H. Snyder. "Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome." Proceedings of the National Academy of Sciences 118, no. 34 (August 16, 2021): e2024358118. http://dx.doi.org/10.1073/pnas.2024358118.

Full text

Abstract:

Although most patients recover from acute COVID-19, some experience postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection (PASC). One subgroup of PASC is a syndrome called “long COVID-19,” reminiscent of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). ME/CFS is a debilitating condition, often triggered by viral and bacterial infections, leading to years-long debilitating symptoms including profound fatigue, postexertional malaise, unrefreshing sleep, cognitive deficits, and orthostatic intolerance. Some are skeptical that either ME/CFS or long COVID-19 involves underlying biological abnormalities. However, in this review, we summarize the evidence that people with acute COVID-19 and with ME/CFS have biological abnormalities including redox imbalance, systemic inflammation and neuroinflammation, an impaired ability to generate adenosine triphosphate, and a general hypometabolic state. These phenomena have not yet been well studied in people with long COVID-19, and each of them has been reported in other diseases as well, particularly neurological diseases. We also examine the bidirectional relationship between redox imbalance, inflammation, energy metabolic deficits, and a hypometabolic state. We speculate as to what may be causing these abnormalities. Thus, understanding the molecular underpinnings of both PASC and ME/CFS may lead to the development of novel therapeutics.

APA, Harvard, Vancouver, ISO, and other styles

39

Challamel, Chloé, Céline Girard, Laurent Misery, Assia Touhouche, Marion Fradet, Cristina Bulai Livideanu, Maria Polina Konstantinou, and Carle Paul. "Efficacité des anti-IL1 dans les syndromes PAPA et le PASH." Annales de Dermatologie et de Vénéréologie - FMC 1, no. 8 (December 2021): A261. http://dx.doi.org/10.1016/j.fander.2021.09.251.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Fritsche, Lars G., Weijia Jin, Andrew J. Admon, and Bhramar Mukherjee. "Characterizing and Predicting Post-Acute Sequelae of SARS CoV-2 Infection (PASC) in a Large Academic Medical Center in the US." Journal of Clinical Medicine 12, no. 4 (February 7, 2023): 1328. http://dx.doi.org/10.3390/jcm12041328.

Full text

Abstract:

Background: A growing number of Coronavirus Disease-2019 (COVID-19) survivors are affected by post-acute sequelae of SARS CoV-2 infection (PACS). Using electronic health record data, we aimed to characterize PASC-associated diagnoses and develop risk prediction models. Methods: In our cohort of 63,675 patients with a history of COVID-19, 1724 (2.7%) had a recorded PASC diagnosis. We used a case–control study design and phenome-wide scans to characterize PASC-associated phenotypes of the pre-, acute-, and post-COVID-19 periods. We also integrated PASC-associated phenotypes into phenotype risk scores (PheRSs) and evaluated their predictive performance. Results: In the post-COVID-19 period, known PASC symptoms (e.g., shortness of breath, malaise/fatigue) and musculoskeletal, infectious, and digestive disorders were enriched among PASC cases. We found seven phenotypes in the pre-COVID-19 period (e.g., irritable bowel syndrome, concussion, nausea/vomiting) and sixty-nine phenotypes in the acute-COVID-19 period (predominantly respiratory, circulatory, neurological) associated with PASC. The derived pre- and acute-COVID-19 PheRSs stratified risk well, e.g., the combined PheRSs identified a quarter of the cohort with a history of COVID-19 with a 3.5-fold increased risk (95% CI: 2.19, 5.55) for PASC compared to the bottom 50%. Conclusions: The uncovered PASC-associated diagnoses across categories highlighted a complex arrangement of presenting and likely predisposing features, some with potential for risk stratification approaches.

APA, Harvard, Vancouver, ISO, and other styles

41

Mylvaganam, Ruben J., Joseph I. Bailey, Jacob I. Sznajder, and Marc A. Sala. "Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection." European Respiratory Review 30, no. 162 (December 15, 2021): 210194. http://dx.doi.org/10.1183/16000617.0194-2021.

Full text

Abstract:

Acute manifestations of SARS-CoV-2 infection continue to impact the lives of many across the world. Post-acute sequelae of coronavirus disease 2019 (COVID-19) may affect 10–30% of survivors of COVID-19, and post-acute sequelae of COVID-19 (PASC)-pulmonary fibrosis is a long-term outcome associated with major morbidity. Data from prior coronavirus outbreaks (severe acute respiratory syndrome and Middle East respiratory syndrome) suggest that pulmonary fibrosis will contribute to long-term respiratory morbidity, suggesting that PASC-pulmonary fibrosis should be thoroughly screened for through pulmonary function testing and cross-sectional imaging. As data accumulates on the unique pathobiologic mechanisms underlying critical COVID-19, a focus on corollaries to the subacute and chronic profibrotic phenotype must be sought as well. Key aspects of acute COVID-19 pathobiology that may account for increased rates of pulmonary fibrosis include monocyte/macrophage–T-cell circuits, profibrotic RNA transcriptomics, protracted elevated levels of inflammatory cytokines, and duration of illness and ventilation. Mechanistic understanding of PASC-pulmonary fibrosis will be central in determining therapeutic options and will ultimately play a role in transplant considerations. Well-designed cohort studies and prospective clinical registries are needed. Clinicians, researchers and healthcare systems must actively address this complication of PASC to minimise disability, maximise quality of life and confront a post-COVID-19 global health crisis.

APA, Harvard, Vancouver, ISO, and other styles

42

Taylor, David C., Anthony J. Salvian, and Christopher R. Shackleton. "Crush syndrome complicating pneumatic antishock garment (PASG) use." Injury 19, no. 1 (January 1988): 43–44. http://dx.doi.org/10.1016/0020-1383(88)90178-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Meyer, Albin, Benjamin Alric, Olivier Dézerald, Elise Billoir, Romain Coulaud, Floriane Larras, Cédric P. Mondy, and Philippe Usseglio-Polatera. "Linking Micropollutants to Trait Syndromes across Freshwater Diatom, Macroinvertebrate, and Fish Assemblages." Water 14, no. 8 (April 7, 2022): 1184. http://dx.doi.org/10.3390/w14081184.

Full text

Abstract:

The ecological quality of freshwater ecosystems is endangered by various micropollutants released into the environment by human activities. The cumulative effects of these micropollutants can affect the fitness of organisms and populations and the functional diversity of stream ecosystems. In this study, we investigated the relationships between the joint toxicity of micropollutants and trait syndromes. A trait syndrome corresponds to a combination of traits that could occur together in communities due to the trait selection driven by exposure to these micropollutants. Our objectives were to (i) identify trait syndromes specific to diatom, macroinvertebrate, and fish assemblages and their responses to exposure, taking into account four micropollutant types (mineral micropollutants, pesticides, PAHs, and other organic micropollutants) and nine modes of action (only for pesticides), (ii) explore how these syndromes vary within and among the three biological compartments, (iii) investigate the trait categories driving the responses of syndromes to micropollutant exposure, and (iv) identify specific taxa, so-called paragons, which are highly representative of these syndromes. To achieve these objectives, we analyzed a dataset including the biological and physico-chemical results of 2007 sampling events from a large-scale monitoring survey routinely performed in French wadeable streams. We have identified five (diatoms), eight (macroinvertebrates), and eight (fishes) trait syndromes, either positively or negatively related to an increasing toxicity gradient of different clusters of micropollutant types or modes of action. Our analyses identified several key trait categories and sets of paragons, exhibiting good potential for highlighting exposure by specific micropollutant types and modes of action. Overall, trait syndromes might represent a novel and integrative bioassessment tool, driven by the diversity of trait-based responses to increasing gradients of micropollutant toxic cocktails.

APA, Harvard, Vancouver, ISO, and other styles

44

Graille, J., M. Beylot-Barry, O. Cogrel, A. Fauconneau, and M. S. Doutre. "PAPA, PASH, PAPASH, PsAPASH, PASS… des syndromes auto-inflammatoires PAS si simples." La Revue de Médecine Interne 36 (December 2015): A205—A206. http://dx.doi.org/10.1016/j.revmed.2015.10.218.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Jason, Leonard A., and Mohammed F. Islam. "A CLASSIFICATION SYSTEM FOR POST-ACUTE SEQUELAE OF SARS CoV-2 INFECTION." Central Asian Journal of Medical Hypotheses and Ethics 3, no. 1 (March 29, 2022): 38–51. http://dx.doi.org/10.47316/cajmhe.2022.3.1.04.

Full text

Abstract:

This study aimed to contribute to the development of a research case definition for post-acute sequelae of SARS CoV-2 infection (PASC) using a PASC data set and experiences from case definitions developed for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Our database included patients with PASC who provided self-report symptomology during the onset of infection and the time of survey completion (post-infection). We found that we could distinguish between those with mild, moderate, and severe PASC. Regarding the proportion meeting an ME/CFS case definition, we found 0% in the mildly impaired group, 30.6% to 62.6% in the moderately impaired group, and 74.3% to 89.0% in the severely impaired group. Based on these preliminary data, we propose a 5-part classification system for PASC. Axis 1 involves the variant of the COVID infection and the type of documentation of the infection. Axis 2 involves the time elapsed since infection. Axis 3 involves the type of medical collateral damage to different organs. Axis 4 involves functional impairment classified into three categories: mild, moderate, or severe. Finally, Axis 5 is the identified symptoms. Finally, if the patient has been sick for 6 or more months, it is important to determine whether the person has met the ME/CFS criteria. This proposed 5-part classification system for PASC might bring considerable clarity to diagnosing PASC.

APA, Harvard, Vancouver, ISO, and other styles

46

Kell, Douglas B., Gert Jacobus Laubscher, and Etheresia Pretorius. "A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications." Biochemical Journal 479, no. 4 (February 23, 2022): 537–59. http://dx.doi.org/10.1042/bcj20220016.

Full text

Abstract:

Post-acute sequelae of COVID (PASC), usually referred to as ‘Long COVID’ (a phenotype of COVID-19), is a relatively frequent consequence of SARS-CoV-2 infection, in which symptoms such as breathlessness, fatigue, ‘brain fog’, tissue damage, inflammation, and coagulopathies (dysfunctions of the blood coagulation system) persist long after the initial infection. It bears similarities to other post-viral syndromes, and to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Many regulatory health bodies still do not recognize this syndrome as a separate disease entity, and refer to it under the broad terminology of ‘COVID’, although its demographics are quite different from those of acute COVID-19. A few years ago, we discovered that fibrinogen in blood can clot into an anomalous ‘amyloid’ form of fibrin that (like other β-rich amyloids and prions) is relatively resistant to proteolysis (fibrinolysis). The result, as is strongly manifested in platelet-poor plasma (PPP) of individuals with Long COVID, is extensive fibrin amyloid microclots that can persist, can entrap other proteins, and that may lead to the production of various autoantibodies. These microclots are more-or-less easily measured in PPP with the stain thioflavin T and a simple fluorescence microscope. Although the symptoms of Long COVID are multifarious, we here argue that the ability of these fibrin amyloid microclots (fibrinaloids) to block up capillaries, and thus to limit the passage of red blood cells and hence O2 exchange, can actually underpin the majority of these symptoms. Consistent with this, in a preliminary report, it has been shown that suitable and closely monitored ‘triple’ anticoagulant therapy that leads to the removal of the microclots also removes the other symptoms. Fibrin amyloid microclots represent a novel and potentially important target for both the understanding and treatment of Long COVID and related disorders.

APA, Harvard, Vancouver, ISO, and other styles

47

Ravaglia, Fabio F. A., M. Goretti Leite, Tiago F. Bracellos, and Alberto Cliquet. "Postambulatory Hand Swelling (Big Hand Syndrome): Prevalence, Demographics, and Association with Dog Walking." ISRN Rheumatology 2011 (December 6, 2011): 1–4. http://dx.doi.org/10.5402/2011/659695.

Full text

Abstract:

Introduction. Postambulatory hand swelling (PAHS) seems to be common in the general population. There are few mention in the medical literature. The objective were (1) to identify prevalence; (2) to compare gender and age groups; (3) to determine if dog owners and walkers are more or less prone. Materials and Methods. 1009 semirandomly surveys were completed from walkers. Age, gender, and dog ownership were assessed. We discussed, among dog owners, whether or not they walk their dog regularly, whether or not they notice swollen hands after walking, and, if so, if the swelling resolves over 24 hours or persists. Results. 699 females and 410 males, among whom, 28.9% of females but only 16.3% of males reported PAHS (P<0.001). Surprisingly, those with swelling were statistically younger than those without (49.2 versus 52.8 years, P=0.003), and dog owners were more likely than nonowners to report swelling (28.1% versus 21.7%; P=0.015). In terms of persistent swelling, this was observed in twice the percentage of females as males (13.3 versus 6.5%) and tended to involve older subjects (54.0 versus 48.8 years), but with no statistical difference significance. Conclusions. PAHS is a relatively common phenomenon, seemingly more common in females.

APA, Harvard, Vancouver, ISO, and other styles

48

Marks, David F. "Converging Evidence of Similar Symptomatology of ME/CFS and PASC Indicating Multisystemic Dyshomeostasis." Biomedicines 11, no. 1 (January 11, 2023): 180. http://dx.doi.org/10.3390/biomedicines11010180.

Full text

Abstract:

The purpose of this article is to review the evidence of similar symptomatology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-acute sequelae of SARS-CoV-2 infection (PASC). Reanalysis of data from a study by Jason comparing symptom reports from two groups of ME/CFS and PASC patients shows a notably similar symptomatology. Symptom scores of the PASC group and the ME/CFS group correlated 0.902 (p < 0.0001) across items. The hypothesis is presented that ME/CFS and PASC are caused by a chronic state of multisystemic disequilibrium including endocrinological, immunological, and/or metabolic changes. The hypothesis holds that a changed set point persistently pushes the organism towards a pathological dysfunctional state which fails to reset. To use an analogy of a thermostat, if the ‘off switch’ of a thermostat intermittently stops working, for periods the house would become warmer and warmer without limit. The hypothesis draws on recent investigations of the Central Homeostasis Network showing multiple interconnections between the autonomic system, central nervous system, and brain stem. The hypothesis helps to explain the shared symptomatology of ME/CFS and PASC and the unpredictable, intermittent, and fluctuating pattern of symptoms of ME/CFS and PASC. The current theoretical approach remains speculative and requires in-depth investigation before any definite conclusions can be drawn.

APA, Harvard, Vancouver, ISO, and other styles

49

Malarvizhi D and Hariharan S. "Correlation of Hand Grip, Gait Speed, Physical Activity with Frailty Index in Geriatric Population." International Journal of Research in Pharmaceutical Sciences 12, no. 1 (January 6, 2021): 208–12. http://dx.doi.org/10.26452/ijrps.v12i1.3980.

Full text

Abstract:

The Geriatric syndrome includes a series of representation which may be related to ageing such as delirium, falls, incontinence and frailty. Frailty is a common clinical syndrome in geriatric population that supports the weight of enhancing the risk of poor health outcomes, including the falls incident, disability, hospitalization and mortality. This study aims to find out the Correlation of Hand Grip, Gait Speed and Physical Activity with Frailty Index in Geriatric Population. It is an observational study done with convenient sampling with 40 participants of both the sexes were selected based on the selection criteria. The frailty of participants was assessed by a questionnaire which contains 41 components known as “Frailty Index”. An administered interviewer reported that. Hand-Held Dynamometer measured hand Grip. A 10-meter walk test assessed gait speed. The Physical Activity Scale assessed physical activity for The Elderly (PASE). The results showed that PASE Score, for the age group between 60-69 years people have high PASE score 100.9 than the age group of peoples 70-79 years, 80-89 years and 90-97 years with a score of 71.49, 36.17, 6.5 respectively. There is a negative correlation of frailty index with hand grip (r = -0.314), gait speed (r = -0.313) and Physical activity. The study concluded that there was a negative correlation of handgrip, gait speed and physical activity with frailty index in the geriatric population.

APA, Harvard, Vancouver, ISO, and other styles

50

Cerretelli, Guia, Ann Ager, Mark J. Arends, and Ian M. Frayling. "Molecular pathology of Lynch syndrome." Journal of Pathology 250, no. 5 (April 2020): 518–31. http://dx.doi.org/10.1002/path.5422.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!